COR · News · 20260805N
Guidance / Outlook
Cencora, Inc. · 2026-08-05 · Importance 51 · Surprise 60 · In source text
Cencora raised its fiscal 2026 adjusted earnings forecast after reporting third-quarter results on August 5, 2026. Reuters attributed the increase to strong demand for specialty medicines. Other coverage reported full-year adjusted EPS guidance of $17.75–$17.95, with the lower end raised, indicating a more favorable earnings outlook despite pricing and funding pressures affecting healthcare distributors.
Key facts
- Cencora raised its full-year fiscal 2026 adjusted EPS guidance to a range of $17.75 to $17.95. source
- Investing.com reported Cencora provided FY 2026 EPS guidance of $17.75-$17.95 and that EPS guidance was in line with or above analyst consensus. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | probable | — | Cencora raised its full-year fiscal 2026 adjusted EPS guidance to a range of $17.75 to $17.95. |